LC-MS/MS determination of helicid in human plasma and its application in pharmacokinetic studies

Helicid is a traditional Chinese medicine used to treat headache and insomnia with definite effects. To facilitate pharmacokinetic studies of helicid in man, a sensitive and specific LC-MS/MS method for the quantitative detection of helicid in human plasma was developed and validated. The method involved the addition of bergeninum as the internal standard (IS), protein precipitation, HPLC separation, and quantification by MS/MS system using negative electrospray ionization in the multiple reaction monitoring mode (MRM). The precursor→product ion transitions were monitored at m/z 282.8→120.9 for helicid and m/z 326.9→192.2 for the IS, respectively. The lower limit of quantification (LLOQ) was 0.2 μg/L. The calibration curves for helicid was linear over a concentration range of 0.2-20 μg/L. The intra- and inter-batch analyses of QC samples at 0.4, 2, 20 μg/L indicated good precision (%R.S.D. between 2.69 and 5.47%) and accuracy (between 96.15 and 105.05%). The helicid was stable in human plasma stored at room temperature for at least 24h, 4°C for at least 24h, -20°C for at least 1 month, and for routine three freeze-thaw cycles. This accurate and specific assay provides a useful method for evaluating the pharmacokinetic profile of helicid in humans.     

华东稻麦轮作生态系统的N2O排放研究

根据对华东稻麦轮作周期的N₂O排放及其影响因子的连续观测结果,分析了N₂O排放时间变化以及施肥、灌溉、温度、土壤湿度和土壤速效N素含量对N₂O排放的影响,同时还比较分析了稻田N₂O和CH₄排放.研究结果表明,稻麦轮作周期内,水稻生长季的N₂O排放量仅占30%,稻田持续淹水可比常规灌溉增加CH₄排放量26%,减少N₂O排放量11～26%.     

含par位点的重组质粒Psjm3的构建及其稳定性研究

利用自然质粒pSC101par位点的分离稳定性功能,构建了含par位点的质粒pSJM4和pSJM3,通过在同样宿主E.coli HB101中的稳定性比较研究表明,不含par位点的重组质粒pSJ3很不稳定,E.coli G3(pSJ3)在培养到第10代时已开始出现pSJ3的丢失,到培养至50代时则已全部丢失;而含par位点的重组质粒pSJM3则表现得十分稳定,E.coli G3-1(pSJM3)经70代培养,仍无明显的质粒丢失现象,其稳定率保持97%以上。通过对不含par和含par的非重组质粒pUC18和pSJM4的稳定性比较也获得同样的结果。通过对E.coliG3(pSJ3)和E.coli G3-1(pSJM3)的产酶活性比较研究表明,G3-1菌株明显高于G3菌株,说明我们构建的重组质粒pSJM3上的par位点功能不仅没有因外源基因的表达而受影响,而且有利于外源基因的表达。     

红壤茶树根层土壤基础呼吸作用和酶活性

对不同树龄茶树根层土壤的呼吸作用(包括代谢熵qCO2)和土壤酶(脲酶、转化酶和酸性磷酸单酯酶)活性进行了研究、不同树龄茶树根层土壤日基础呼吸作用强度(36．23—58．52mg·kg^-1·d^-1)和日代谢墒(0．30一0．68)都以40和90年茶树较为接近,分别显著大于和小于10年树龄茶树根层土壤;服酶活性(41．48—47、72mg·kg^-1·d^-1)则三者间差异不大,虽然随树龄增长而下降;转化酶活性(189．29—363．40mg·kg^-1·d^-1)也随树龄增长而下降,并且10年茶树根层土壤显著大于40和90年树龄茶树;而酸性磷酸单酯酶活性(444．22—828．32mg·kg^-1·d^-1)相反,随树龄增长而增强．结果表明,土壤基础呼吸作用、代谢熵和3种土壤酶活性都与茶树树龄、土壤pH、土壤有机碳、土壤全氮、土壤可活性酚总量、及土壤微生物生物量密切相关．     

Tissue microarray study for classification of breast tumors

Clinical and pathological heterogeneity of breast cancer hinders selection of appropriate treatment for individual cases. Molecular profiling at gene or protein levels may elucidate the biological variance of tumors and provide a new classification system that correlates better with biological, clinical and prognostic parameters. We studied the immunohistochemical profile of a panel of seven important biomarkers using tumor tissue arrays. The tumor samples were then classified with a monothetic (binary variables) clustering algorithm. Two distinct groups of tumors are characterized by the estrogen receptor (ER) status and tumor grade (p = 0.0026). Four biomarkers, c-erbB2, Cox-2, p53 and VEGF, were significantly overexpressed in tumors with the ER-negative (ER-) phenotype. Eight subsets of tumors were further identified according to the expression status of VEGF, c-erbB2 and p53. The malignant potential of the ER-/VEGF+ subgroup was associated with the strong correlations of Cox-2 and c-erbB2 with VEGF. Our results indicate that this molecular classification system, based on the statistical analysis of immunohistochemical profiling, is a useful approach for tumor grouping. Some of these subgroups have a relative genetic homogeneity that may allow further study of specific genetically-controlled metabolic pathways. This approach may hold great promise in rationalizing the application of different therapeutic strategies for different subgroups of breast tumors.     

荧光假单胞菌抗噬菌体菌株的选育

本实验从荧光假单胞菌（Ｐｓｅｕｄｏｍｏｎａｓｆｌｕｏｒｅｓｃｅｎｓ）ＡＳ—３菌株的不正常发酵液中分离到一种噬菌体,将其命名为ＰＦＡＳ。ＡＳ—３菌株能利用葡萄糖发酵产生Ｄ－异维生素Ｃ的前体物质２－酮基－Ｄ－葡萄糖酸。电镜观察表明ＰＦＡＳ噬菌体呈蝌蚪形,具有直径为６６ｎｍ的六角形头部及长１１７ｎｍ的尾部。通过紫外线诱变及自然选育两种途径,配合简便有效的初筛方法,经多次分离、纯化、复筛最终在摇并发酵试验中获得６株产量稳定地高于对照敏感菌的抗噬菌体菌株,可望用于生产。     

In vitro and in vivo growth and casein gene expression of mouse mammary tumor epithelial cells in response to hormones

Cells from autochthonous mouse mammary carcinomas which display estrogen-independent growth _vivo were studied for their hormonal responses in primary culture. A culture system employing insulin-supplemented, serum-free medium and basement membrane Matrigel as a substratum was used to cultivate tumor cells. The cells did not exhibit in vitro estrogenor prolactin-dependent growth. Primary tumors still displayed a constitutional expression of α-, β-, and γ-casein mRNAs. These messages were dramatically reduced during the culture period. However, seven to eightfold increases in α- and β-casein mRNAs were inducible in the 5-day cultures by treatment with prolactin and hydrocortisone. If the hormones were present through a 2-week culture period, the levels of α-, β-, and γ-casein mRNAs in the cells were maintained and displayed in a time-dependent increase with a peak at 10–14 days. The accumulation of β-casein mRNA in vitro did not require DNA synthesis. Administration of prolactin directly into the growing tumors in vivo could also enhance β-casein mRNA levels in the tumor cells. Morphological studies of the cells cultured in the presence of prolactin and hydrocortisone did not reveal visible changes compared with those without hormonal treatment. Transplantation of tumor cells cultured in the presence or absence of hormones resulted in the development of tumors in mice at approximately the same time. The current studies suggest that the autochthonous mammary tumor cells, independent of estrogen for cell growth, were still inducible for casein gene expression in vitro and in vivo by appropriate hormones. The induction and maintenance of casein messages by a single hormonal treatment did not appear to correlate with morphology and DNA synthesis of cells in vitro or with tumor-producing capacities in vivo.